研究项目库 / NCT07367516

TQB6411 Injection用于食管癌的I 期 / II 期研究

这是一项关于食管癌的I 期 / II 期研究,登记的药物或干预包括TQB6411 Injection,当前状态为招募中。登记地点显示中国合肥、北京、福州、兰州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

一分钟看懂

这是一项关于食管癌的I 期 / II 期研究,登记的药物或干预包括TQB6411 Injection,当前状态为招募中。登记地点显示中国合肥、北京、福州、兰州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

药物或干预

TQB6411 Injection · I 期 / II 期

中国哪些地方有记录

以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。

  • The Second Affiliated Hospital of Anhui Medical University · 合肥
  • Cancer Hospital Chinese Academy of Medical Sciences · 北京
  • Fujian Cancer Hospital · 福州
  • Gansu Provincial Tumor Hospital · 兰州
  • The First Affiliated Hospital of Shantou University Medical College · 汕头
  • Guangxi Medical University Cancer Hospital · 南宁
  • Guizhou Provincial People's Hospital · 广西壮族自治区
  • The Second Affiliated Hospital of Zunyi Medical University · 遵义
  • Harbin Medical University Cancer Hospital · 哈尔滨
  • Anyang Cancer Hospital · 安阳
  • The Second People's Hosital of Jiaozuo · 焦作
  • Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital) · 洛阳
  • The first affiliated hospital of Zhengzhou university · 郑州
  • Zhengzhou Central Hospital · 郑州
  • Hunan Provincial People's Hospital · 长沙
  • Jiangsu Cancer Hospital · 南京
  • Jiangsu Provincial Hospital of Traditional Chinese Medicine · 南京
  • Northern Jiangsu People's Hospital · 扬州
  • The first hospital of jilin university · 长春
  • Jilin Cancer Hospital · 长春
  • Linyi cancer Hospital · 临沂
  • Shanghai Chest Hospital · 上海
  • Shanxi Bethune Hospital · 太原
  • The Second Affiliated Hospital of Air Force Medical University · 西安
  • Sichuan cancer hosipital · 成都
  • Sichuan Provincial People's Hospital · 成都
  • Affiliated Hospital of Southwest Medical University · 泸州
  • Tianjin Medical University Cancer Institute & Hospital · 天津
  • The First Affiliated Hospital of Wenzhou Medical University · 温州
  • Zhongshan Hospital Fudan University · 上海

公开的入选条件

  • * Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance.
  • * Age between 18 and 75 years old (inclusive)
  • * Eastern Cooperative Oncology Group (ECOG) score of 0-1
  • * Expected survival \>12 weeks
  • * At least one measurable lesion per RECIST v1.1
  • * Laboratory criteria(no hematopoietic growth factor correction within 7 days):
  • Hemoglobin (HGB) ≥90 g/L;
  • Absolute neutrophil count (NEUT) ≥1.5×10⁹/L;

联系前需要确认

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

查看登记信息

登记号:NCT07367516;登记信息更新于 2026-09-15。

查看原始登记记录